Solid Biosciences (SLDB) CRO sells 12,348 shares to cover RSU tax

Rhea-AI Filing Summary

Solid Biosciences Inc. insider transaction: Chief Regulatory Officer Jessie Hanrahan reported an automatic sale of common stock tied to tax withholding. On February 4, 2026, 12,348 shares of common stock were sold at a weighted average price of $6.4419 per share to cover withholding taxes after restricted stock units vested. The filing notes this was executed under a pre-established durable automatic sale instruction and is not a discretionary trade. After the transaction, Hanrahan beneficially owned 70,327 shares of Solid Biosciences common stock in direct ownership.

Insider Trade Summary

Net Seller: 12,348 shares ($79,545)

Net Sell 1 txn

Insider Hanrahan Jessie

Role Chief Regulatory Officer

Sold 12,348 shs ($80K)

Type	Security	Shares	Price	Value
Sale	Common Stock	12,348	$6.4419	$80K

Holdings After Transaction: Common Stock — 70,327 shares (Direct)

Footnotes (1)

1. This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units pursuant to a durable automatic sale instruction letter adopted by Dr. Hanrahan on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Hanrahan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hanrahan Jessie

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MA 02129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Regulatory Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/04/2026		S		12,348(1)	D	$6.4419(2)	70,327	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units pursuant to a durable automatic sale instruction letter adopted by Dr. Hanrahan on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Hanrahan.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

	/s/ Kimberly Cornwell as attorney-in-fact for Jessie Hanrahan	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SLDB Chief Regulatory Officer report on February 4, 2026?

SLDB’s Chief Regulatory Officer, Jessie Hanrahan, reported selling 12,348 shares of common stock on February 4, 2026 at a weighted average price of $6.4419 per share. The transaction was related to tax withholding following the vesting of restricted stock units.

Why did Jessie Hanrahan sell Solid Biosciences (SLDB) shares in this Form 4 filing?

The sale was made solely to cover withholding taxes triggered by the vesting of previously granted restricted stock units. It was executed under a durable automatic sale instruction letter and is explicitly described as not representing a discretionary trade by Jessie Hanrahan.

How many SLDB shares does Jessie Hanrahan own after the reported transaction?

After the reported sale, Jessie Hanrahan beneficially owns 70,327 shares of Solid Biosciences common stock. The filing shows these shares as directly held, reflecting the remaining equity stake following the tax-related sell-to-cover transaction on February 4, 2026.

What price range applied to the SLDB shares sold by Jessie Hanrahan?

The weighted average sale price was $6.4419 per share, with individual trades executed between $6.28 and $6.60 per share. The filing states that full pricing details for each transaction within this range are available upon request from the issuer or relevant parties.

Is the SLDB insider sale by Jessie Hanrahan considered discretionary trading?

No, the filing specifies that the sale does not represent a discretionary trade by Jessie Hanrahan. It was carried out under a durable automatic sale instruction to effect a sell-to-cover election for withholding taxes upon vesting of restricted stock units.

What is Jessie Hanrahan’s role at Solid Biosciences (SLDB) in this Form 4?

In this Form 4, Jessie Hanrahan is identified as an officer of Solid Biosciences, serving as Chief Regulatory Officer. The reported transaction involves common stock held directly, associated with compensation in the form of restricted stock units that recently vested.